Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of M100907 for sleep maintenance insomnia
2006-005303-34Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Insomnia comparing M100907 2 mg/day with Placebo (2 arms). Primary endpoint: Night polysomnography wake time after sleep onset (WASO). Started Mar 2007; status: completed.
02
Drugs
volinanserin
03
Conditions
Insomnia
Beyond the preview
Go deeper on 2006-005303-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005303-34.